Soluble immune-checkpoint factors: a potential immunotherapy biomarker
Journal of Clinical Investigation - Cardiology
APRIL 1, 2024
There is unmet need for additional biomarkers to better select patients with non–small cell lung cancer (NSCLC) that are likely to benefit from immunotherapy in order to improve patient outcomes, reduce patient toxicity, and relieve the growing burden of healthcare costs.
Let's personalize your content